Study Evaluates Inhaled Nitric Oxide for COVID-19
Researchers assessed outcomes of INOmax inhaled nitric oxide for COVID-19 patients hospitalized with mild-to-moderate ARDS.
Researchers assessed outcomes of INOmax inhaled nitric oxide for COVID-19 patients hospitalized with mild-to-moderate ARDS.
Two experts on inhaled nitric oxide explain the physiological effects and properties that make iNO a potential therapeutic agent in the battle against COVID-19.
The patient was treated under an emergency IND filed by a qualified Investigator and approved by the US FDA, according to the manufacturer Vero Biotech.
Low levels of both oxygen and nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.
Read More